دورية أكاديمية

Precision Promise (PrP) Bayesian platform trial for metastatic pancreatic cancer (mPDAC): Results of the first experimental arm, SM-88 as second line therapy.

التفاصيل البيبلوغرافية
العنوان: Precision Promise (PrP) Bayesian platform trial for metastatic pancreatic cancer (mPDAC): Results of the first experimental arm, SM-88 as second line therapy.
المؤلفون: Oberstein, Paul Eliezer, wang-gillam, Andrea, Varghese, Anna M., Ko, Andrew H., Hendifar, Andrew Eugene, Ocean, Allyson J., McGlothlin, Anna, Graves, Todd, Berry, Scott M., Detry, Michelle A., Fitzgerald, Mark, Bosse, Anna, Moravek, Cassadie, Feehan, Kelly, Howland, Carrie Meghann, Berry, Donald A., Simeone, Diane M., Picozzi, Vincent J.
المصدر: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p675-675, 117p
قاعدة البيانات: Supplemental Index
الوصف
تدمد:0732183X
DOI:10.1200/JCO.2024.42.3_suppl.675